Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study.
Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Mohammad Porras N, Matsuo Y, Kiefer L, Knulst AC, Maurer M, Ritchie C, Rudenko M, Kocatürk E, Criado RFJ, Gregoriou S, Bobylev T, Kleinheinz A, Takahagi S, Hide M, Giménez-Arnau AM, Salman A, Kara RO, Dikicier BS, van Doorn MBA, Thomsen SF, van den Reek JMPA, Röckmann H. Soegiharto R, et al. Among authors: rockmann h. Allergy. 2024 Oct 8. doi: 10.1111/all.16334. Online ahead of print. Allergy. 2024. PMID: 39377745
Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation.
Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Porras NM, Matsuo Y, Kiefer L, Knulst AC, Maurer M, Ritchie C, Rudenko M, Kocatürk E, Criado RFJ, Gregoriou S, Bobylev T, Kleinheinz A, Takahagi S, Hide M, Giménez-Arnau AM, Salman A, Kara RO, Sevimli Dikicier B, van Doorn MBA, Thomsen SF, van den Reek JMPA, Röckmann H. Soegiharto R, et al. Among authors: rockmann h. JAMA Dermatol. 2024 Sep 1;160(9):927-935. doi: 10.1001/jamadermatol.2024.2056. JAMA Dermatol. 2024. PMID: 39018068
High-dose omalizumab use in patients with chronic spontaneous urticaria.
Alizadeh Aghdam M, van den Broek F, Rijken F, Knulst AC, Röckmann H. Alizadeh Aghdam M, et al. Among authors: rockmann h. J Allergy Clin Immunol Pract. 2020 Apr;8(4):1426-1427.e1. doi: 10.1016/j.jaip.2019.10.018. Epub 2019 Oct 31. J Allergy Clin Immunol Pract. 2020. PMID: 31678293 No abstract available.
Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria.
Alizadeh Aghdam M, Knol EF, van den Elzen M, den Hartog Jager C, van Os-Medendorp H, Knulst AC, Otten HG, Röckmann H. Alizadeh Aghdam M, et al. Among authors: rockmann h. Clin Exp Allergy. 2020 Mar;50(3):364-371. doi: 10.1111/cea.13566. Epub 2020 Feb 7. Clin Exp Allergy. 2020. PMID: 31925825 Free PMC article. Clinical Trial.
Effective omalizumab interval prolongation in the treatment of chronic urticaria.
Alizadeh Aghdam M, Pieterse RH, Kentie PA, Rijken F, Knulst AC, Röckmann H. Alizadeh Aghdam M, et al. Among authors: rockmann h. J Allergy Clin Immunol Pract. 2020 Nov-Dec;8(10):3667-3668.e1. doi: 10.1016/j.jaip.2020.06.056. Epub 2020 Jul 14. J Allergy Clin Immunol Pract. 2020. PMID: 32679351 Free article. No abstract available.
Systemic and local evidence for complement involvement in chronic spontaneous urticaria.
Alizadeh Aghdam M, van den Elzen M, van Os-Medendorp H, van Dijk MR, Knol EF, Knulst AC, Röckmann H, Otten HG. Alizadeh Aghdam M, et al. Among authors: rockmann h. Clin Transl Allergy. 2021 Jul 3;11(5):e12011. doi: 10.1002/clt2.12011. eCollection 2021 Jul. Clin Transl Allergy. 2021. PMID: 34262691 Free PMC article.
41 results